Head and neck for Viralytics

By Kate McDonald
Tuesday, 09 December, 2008

Sydney biotech Viralytics has been authorised to start a trial of its Cavatak oncolytic virus technology in head and neck cancers.

The company is running Phase I trials of the technology in late stage melanoma, prostate and breast cancers.

The new trial will involve nine patients with recurrent, inoperable tumours of the head and neck.

Cavatak is a coxsackievirus-based formulation which attaches itself to receptors on the cell surface that are highly expressed in some solid tumours.

Related News

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...

Over-the-counter pain relievers may improve concussion recovery

People who take over-the-counter pain relievers after a concussion may recover faster than those...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd